Acute exacerbations (Number of patients, Severity, Frequency of AE, Time to AE) in COPD patients between the intervention and the control group Lung function in COPD patients between the intervention and the control group Blood inflammatory markers between the intervention and the control group Quality of life in COPD patients between the intervention and the control group Sleep quality in COPD patients between the intervention and the control group Acute exacerbations COPD Lung funct
Conditions
Interventions
The intervention group will receive a positive pressure room with an air quality sensor installed in the bedroom and operated continuously for 6 months. Participants must stay in the bedroom for at l
Experimental Other,No Intervention Other
Positive Pressure Group,Control
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1 Diagnosed with chronic obstructive pulmonary disease (COPD) by a physician with ICD10 codes J43 and J44 2 Classified as GOLD E or exacerbation prone according to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2 or more moderate exacerbations or 1 or more hospitalization in the past 12 months 3 History of at least 1 exacerbation between January and May during 2022 to 2025 4 Clinically stable for at least 12 weeks after the most recent exacerbation 5 Residence in a concrete building with a separate, enclosed bedroom 6 Residence has WiFi or free WiFi access to collect air pollution data from sensors 7 Willingness to participate and provide informed consent
Exclusion criteria
Exclusion criteria: 1 Active Smoking 2 Stays in the residence for less than 6 consecutive hours per day. 3 Co-morbidity lung cancer, interstitial lung diseases, ischemic heart disease, heart failure, arrhythmia, Renal Replacement Therapy, OSA, cognitive impairment, moderate or severe depressive disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exacerbation 6 month Exacerbation ((Number of patients, Severity, Frequency of AE, Time to AE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life baseline, 1 month, 3 month, 6 month EQ-5D-5L questionnaire,Complete Blood Count Baseline, 1 weeks, 1month, 3 month, 6 month Complete Blood Count ,C-Reactive Protein Baseline, 1 weeks, 1month, 3 month, 6 month C-Reactive Protein level,Sleep quality baseline, 1 month, 3 month, 6 month Thai-PSQI score,Sick building syndrome symptom Baseline, 1 weeks, 1month, 3 month, 6 month SBS questionnaire score,COPD clinical Baseline, 1 weeks, 1month, 3 month, 6 month MRC score and CAT score,Lung function Baseline, 1 weeks, 1month, 3 month, 6 month Spirometry : FEV1, FVC, FEV1/FVC, PEF, FEF25-75,Cardiopulmonary fitness baseline, 3 month, 6 month 6 minute walk distance test : meters,Death 6 month Number and time to death,Length of hospital stay due to AE 6 month Length of hospital stay due to AE | — |
Countries
Thailand
Contacts
Public ContactJinjuta Panumasvivat
Faculty of Medicine, Chiang Mai University
Outcome results
None listed